Inhibikase Deferred Long Term Liab vs Retained Earnings Analysis
IKT Stock | USD 1.84 0.03 1.66% |
Inhibikase TherapeuticsInc financial indicator trend analysis is infinitely more than just investigating Inhibikase TherapeuticsInc recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inhibikase TherapeuticsInc is a good investment. Please check the relationship between Inhibikase TherapeuticsInc Deferred Long Term Liab and its Retained Earnings accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.
Deferred Long Term Liab vs Retained Earnings
Deferred Long Term Liab vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inhibikase TherapeuticsInc Deferred Long Term Liab account and Retained Earnings. At this time, the significance of the direction appears to have strong relationship.
The correlation between Inhibikase TherapeuticsInc's Deferred Long Term Liab and Retained Earnings is 0.78. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Inhibikase TherapeuticsInc, assuming nothing else is changed. The correlation between historical values of Inhibikase TherapeuticsInc's Deferred Long Term Liab and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Inhibikase TherapeuticsInc are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Deferred Long Term Liab i.e., Inhibikase TherapeuticsInc's Deferred Long Term Liab and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Inhibikase TherapeuticsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inhibikase TherapeuticsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.At this time, Inhibikase TherapeuticsInc's Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.09 in 2024, despite the fact that Enterprise Value is likely to grow to (1.9 M).
2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 11.4M | 6.7K | 177.4K | 168.5K | Depreciation And Amortization | 14.8M | 6.7K | 177.4K | 168.5K |
Inhibikase TherapeuticsInc fundamental ratios Correlations
Click cells to compare fundamentals
Inhibikase TherapeuticsInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inhibikase TherapeuticsInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Current Liabilities | 4.3M | 4.7M | 4.1M | 3.7M | 3.4M | 3.7M | |
Net Tangible Assets | (778.0K) | (4.5M) | 9.8M | 38.4M | 44.2M | 46.4M | |
Retained Earnings | (12.2M) | (15.0M) | (29.8M) | (47.9M) | (66.9M) | (63.6M) | |
Accounts Payable | 1.0M | 1.7M | 1.1M | 1.2M | 646.8K | 1.0M | |
Other Assets | 2.9K | 829.2K | 1.6M | 1.0 | 1.15 | 1.09 | |
Total Current Assets | 35.4K | 14.8M | 42.5M | 24.4M | 14.2M | 13.4M | |
Other Current Liab | 1.7M | 632.9K | 2.7M | 2.4M | 2.3M | 1.9M | |
Total Assets | 38.3K | 14.8M | 42.5M | 24.9M | 14.5M | 18.3M | |
Short Long Term Debt Total | 373.8K | 319.0K | 248.9K | 351.3K | 622.0K | 393.9K | |
Total Stockholder Equity | (4.5M) | 9.8M | 38.4M | 21.0M | 11.0M | 13.7M | |
Net Debt | 355.3K | (13.6M) | (40.5M) | (6.8M) | (8.5M) | (9.0M) | |
Cash | 18.5K | 14.0M | 40.8M | 7.2M | 9.2M | 13.1M | |
Cash And Short Term Investments | 18.5K | 14.0M | 40.8M | 23.1M | 13.3M | 16.8M | |
Common Stock Shares Outstanding | 1.7M | 1.7M | 3.0M | 4.2M | 5.3M | 3.2M | |
Liabilities And Stockholders Equity | 38.3K | 14.8M | 42.5M | 24.9M | 14.5M | 18.3M | |
Non Current Liabilities Total | 275.4K | 276.5K | 2.7M | 205.5K | 90.1K | 85.6K | |
Other Current Assets | 16.9K | 54.8K | 1.5M | 163.5K | 959.0K | 567.6K | |
Other Stockholder Equity | 7.7M | 24.8M | 68.2M | 68.8M | 77.9M | 46.4M | |
Total Liab | 4.5M | 5.0M | 4.1M | 3.9M | 3.5M | 3.3M | |
Net Invested Capital | (4.1M) | 10.1M | 38.7M | 21.0M | 11.0M | 14.0M | |
Net Working Capital | (4.2M) | 10.1M | 38.4M | 20.7M | 10.8M | 13.4M | |
Short Term Debt | 98.4K | 42.5K | 248.9K | 145.8K | 531.9K | 558.5K |
Pair Trading with Inhibikase TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inhibikase TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Inhibikase Stock
0.67 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Inhibikase TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inhibikase TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inhibikase TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inhibikase TherapeuticsInc to buy it.
The correlation of Inhibikase TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inhibikase TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inhibikase TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inhibikase TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibikase TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Inhibikase Stock please use our How to Invest in Inhibikase TherapeuticsInc guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Inhibikase Stock analysis
When running Inhibikase TherapeuticsInc's price analysis, check to measure Inhibikase TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase TherapeuticsInc is operating at the current time. Most of Inhibikase TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Inhibikase TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase TherapeuticsInc's price. Additionally, you may evaluate how the addition of Inhibikase TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Inhibikase TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase TherapeuticsInc. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.23) | Revenue Per Share 0.034 | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (1.20) |
The market value of Inhibikase TherapeuticsInc is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Inhibikase TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase TherapeuticsInc's market value can be influenced by many factors that don't directly affect Inhibikase TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.